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liver failure, CSI: clinically significant bacterial infections, FCN: ficolin, MASP: 
mannan-binding lectin serine proteases, MBL: mannan-binding lectin, MELD: 
model for end-stage liver disease, HBV: hepatitis B virus, HCV: hepatitis C 
virus, SBP: spontaneous bacterial peritonitis, SNP: single nucleotide 
polymorphism, sPRM: soluble pattern recognition molecule 
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ABSTRACT  
Background&Aims: Lectin pathway molecules of the complement system 
are synthesized by hepatocytes and have pivotal role in innate host defense 
against infectious organisms. Ficolins(FCNs) act as soluble pattern 
recognition molecules, while mannan-binding lectin serine proteases(MASPs) 
do as effector molecules in elimination of pathogens. We aimed to study the 
significance of low level of these molecules in the development of cirrhosis-
associated bacterial infections, which has not been elucidated so far.  
Methods: Sera of 266 stable outpatients with cirrhosis and 160 healthy 
subjects were assayed for a panel of lectin molecules (FCN-2, FCN-3 and 
MASP-2) by ELISA. In cirrhosis, a 5-year follow-up observational study was 
conducted to assess a possible association between lectin levels and 
development of clinically significant bacterial infections(CSI). Results: FCN-2, 
FCN-3 and MASP-2 levels were significantly lower in cirrhosis compared to 
healthy subjects and decreased according to disease severity (p<0.001 for all 
molecules).  In Kaplan-Meier analysis, development of CSI was associated 
with low level of FCN-2 (<427ng/ml, pLogRank=0.047) and FCN-3 
(<4857ng/ml, pLogRank=0.029), but not with MASP-2 deficiency (<100ng/ml, 
pLogRank=0.306). Combined FCN deficiency was associated with increased 
risk of development of bacterial infections in a step-wise manner. Patients 
with low level of both FCNs had higher cumulative probability of CSI (63.8%) 
compared to those with low level of one or normal FCN (52.7% and 45.7%, 
pLogRank=0.016). Neither FCN serum profile, nor MASP-2 deficiency were 
associated with infection-related mortality. Conclusions: Low level of FCNs 
associated with hepatic insufficiency might be considered as an additional 
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constituent of cirrhosis-associated immune dysfunction. 
 
Word count for abstract: 248 
Key words: ficolin, mannan-binding lectin serine protease, cirrhosis, bacterial 
infection, mortality 
 
Key Points 
• The present 5-year follow-up cohort study comprehensively evaluated 
associations of serum level of lectin pathway molecules with disease 
specific characteristics of cirrhosis and also their role in the 
development of bacterial infections, that has not been assessed 
previously. 
• Ficolins(FCN-2, FCN-3) and mannan-binding lectin serine protease-
2(MASP-2) serum levels were decreased in cirrhosis and were 
associated with disease severity. 
• Low level of individual or combined FCNs, but not MASP-2 deficiency 
constituted higher risk for the development of cirrhosis-associated 
bacterial infections. 
• These results highlight deleterious effect of decreased level of soluble 
pattern recognition molecules in cirrhosis, and might be considered 
additional constituents of cirrhosis-associated immune dysfunction. 
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INTRODUCTION 
Multiple levels of immune dysfunction have been found in patients with 
cirrhosis rendering them susceptible to various bacterial infections [1]. 
Infectious episodes are common causes of clinical deterioration in this patient 
group [2] as they play a substantial role in the development of disease specific 
complications and mortality [3,4]. Prevention of bacterial infections in cirrhosis 
is of paramount importance, which requires early identification of patients at 
high risk for the development of these episodes. Only some clinical predictors 
of bacterial infections, such as advanced disease stage [5] and the presence 
of gastrointestinal hemorrhage [6] have been known for a long while. Recently, 
various genetic polymorphisms affecting different functions of innate immune 
system were identified to have a substantial impact on the development of 
bacterial infections in cirrhosis. These functional variations, assessed either 
by serologic [7,8] or single nucleotide polymorphism(SNP) based genetic 
methods [9–12], are considered to further abolish the pre-existing immune 
dysfunction in cirrhosis. Most of these studies, however focused on one or two 
single markers and primarily assessed the risk for the development of 
spontaneous bacterial peritonitis(SBP) and not for other type of bacterial 
infections. Nonetheless, in cirrhosis, SBP comprises only up to 25% of the 
infectious episodes.  
Lectin pathway molecules of the complement system are synthesized 
in the liver and have pivotal roles in the innate host defense against infectious 
organisms. Mannose-binding lectin(MBL) and ficolins(FCNs) act as soluble 
pattern recognition molecules(sPRM), while mannan-binding lectin serine 
proteases(MASPs) do as effector molecules in elimination of the pathogens 
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[13]. Low levels of the functional proteins increase the risk of various 
infectious diseases mostly in immune-deficient conditions [14–16]. 
Association of deficiencies in lectin pathway molecules with the development 
of infectious episodes in patients with cirrhosis is quite reasonable, but has 
scarcely been investigated. Our group has previously demonstrated, that the 
absolute MBL deficiency is a risk for the development of clinically significant 
bacterial infections (CSI) independently from both the disease severity and 
the presence of co-morbidity. Furthermore, in a small study of Chong et al., 
the MBL2 deficient genotype predisposed patients with hepatitis B virus(HBV) 
induced liver cirrhosis to develop SBP [17]. 
  In the present study, we aimed to assess the serum levels of various 
lectin pathway molecules in a large cohort of stable outpatients with cirrhosis 
and also their association with the disease specific characteristics. 
Additionally, in a 5-year follow-up observational study we aimed to evaluate 
whether serum levels of various lectin pathway molecules constitute a risk for 
the development of cirrhosis-associated bacterial infections.  
 
PATIENTS AND METHODS  
Patient population 
We performed a cohort study among adult patients with established diagnosis 
of cirrhosis of different etiologies in a tertiary care referral center of Hungary 
(Division of Gastroenterology Department of Internal Medicine, Clinical 
Center, University of Debrecen). The present study population is a part of our 
entire patient cohort comprising a total of 404 patients with cirrhosis and 
recruited consecutively between May 1, 2006 and December 31, 2010 from 
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the outpatient clinic during regular or extraordinary follow-up visits and also 
from the inpatient ward owing to hospitalization with an acute decompensation 
(AD) episode [18]. In this study only stable outpatients with available serum 
samples (n=266) were included.   
Clinical characteristics of patients at inclusion are presented in Table 1. 
Blood samples, routine laboratory data and detailed clinical phenotype were 
captured at inclusion. Clinical data were determined by in-depth review of the 
patients’ medical records using a structured interview. Medical records that 
documented age at diagnosis, etiology, presence of hepatocellular carcinoma, 
esophageal varices, extrahepatic co-morbidities, history of previous AD 
episode(s), and cirrhosis-related medication were retrospectively analyzed for 
the period prior to the observational follow-up study. At enrolment, disease 
severity assessed by liver-oriented scores (Child-Pugh and MELD) was 
determined. 
 
Phenotypical characterization of patients during follow-up 
Patients were enrolled into an observational follow-up study, where the 
attending gastroenterologist registered date and type of clinically significant 
bacterial infections (CSI) warranted hospital admission. Follow-up period 
lasted 5 years, or until death/loss of follow-up. The median follow-up was 979 
days (IQR: 331-1825). Collected data were transferred and stored in a 
database. At the end of the study period, December 31, 2013, all clinical data 
were extracted for further analysis.  
Development of CSI was carefully established by compatible clinical 
symptoms and findings, laboratory data (leucocyte count, high-sensitivity C-
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reactive protein and procalcitonin, results of urine analysis (sediment) and 
imaging findings (abdominal ultrasound and chest X-ray) and if ascites was 
present the result of diagnostic tap (neutrophil count and ascites culture) was 
considered. Based on the results of this procedure, cultures from specific sites 
(sputum, urine, wound discharge, etc.) were obtained according to location of 
infection, though blood cultures were obtained in sepsis, or if the location of 
the infection could not be clearly identified. Regarding laboratory results, 
elevated leucocyte count (absolute >10.8 G/L or relative [in patients with 
leukopenia]: double of count at former visits) with an elevated neutrophil rate 
(>76%) and increased serum levels of CRP (>10.0 mg/L) and/or PCT (>0.15 
µg/L) [19] were considered to support the diagnosis of infection. Based on 
specific clinical symptoms and findings the following infections were 
diagnosed. Further characterization of bacterial infections was done on the 
basis of conventional criteria [20–23].  (1) Spontaneous bacterial peritonitis: 
neutrophil cell count >250/mm3 and/or positive culture of ascitic fluid, in the 
absence of intra-abdominal source of infection. (2) Urinary tract infection: 
presence of dysuria, pyuria (leucocyte >10/mm3) and positive urine culture. 
(3) Pneumonia: presence of cough and expectoration, positive chest X-ray, 
positive sputum culture. (4) Miscellaneous: skin and soft tissue, biliary tract, 
orocavital, intestinal tract infection, osteomyelitis, endocarditis. (5) Bacterial 
infection with unknown origin: positive blood culture in the absence of site-
specific infection.  
The healthy control group consisted of 160 age- and gender-matched 
individuals (male/female: 72/88, age: 51.5±16.9 years) selected from 
consecutive blood donors in Debrecen. The control subjects did not have any 
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known gastrointestinal or liver diseases. 
 
Serological analysis 
Blood samples were obtained at enrolment from each patient and were frozen 
at -70°C until testing collectively after end of the study period.  
 Serum level of MASP-2 was determined by a commercially available 
solid-phase enzyme-linked immunoassay(ELISA), according to the 
manufacturer’s instructions (Hycult Biotechnology, Uden, Netherlands). 
MASP-2 deficiency was defined a level of <100ng/ml in agreement with 
literature data [24].  
 Serum level of L-ficolin (Liver ficolin, ficolin-2 [FCN-2]) and H-ficolin, 
Hakata ficolin, ficolin-3 [FCN-3]) were determined by an in-house developed 
double-antibody sandwich ELISA. Since no definition exists for FCN 
deficiency, low level of FCN-2 (<427ng/ml) and FCN-3 (<4857ng/ml) were 
determined arbitrarily corresponding to the 25th serum level percentile of the 
patients.  
  Detailed description of these experiments such as analytical properties 
are presented in the Supplementary Material. 
 
Ethical considerations 
The study protocol was approved by Regional and Institutional Research 
Ethics Committee of University of Debrecen and the National Scientific and 
Research Ethics Committee (DEOEC-RKEB/IKEB 5306-9/2011, 
3885/2012/EKU [60/PI/2012]). Each patient or legal surrogate was informed of 
the nature of the study and signed an informed consent form. 
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Statistical analysis 
Variables were tested for normality using Shapiro Wilk’s W test. Continuous 
variables were summarized as means (standard deviation [SD]) or as 
medians (interquartile range [IQR, lowest 25%- highest 25%]) according to 
their homogeneity. Categorical variables were compared with Fisher’s exact 
test or χ
2 test with Yates correction, as appropriate. Continuous variables 
were compared with Mann-Whitney U test or Kruskal-Wallis H test with 
Dunn’s multiple comparison post hoc analysis. Paired samples were analyzed 
by Wilcoxon signed rank test. The Spearman’s nonparametric rank correlation 
test was used to determine correlations. Kaplan–Meier analysis was used to 
calculate the cumulative probability of adverse outcome (CSI and mortality). 
Differences in observed probabilities were assessed by the log-rank test. The 
association between categorical clinical variables or serum levels of lectin 
pathway molecules and adverse disease outcomes during follow-up was 
assessed by univariate Cox-regression analysis. Multivariate analyses were 
performed with backward elimination procedure and likelihood ratio test to 
identify independent predictors. Associations are given as hazard ratio [HR] 
with 95% confidence intervals [CI]. For statistical analysis and graphical 
presentation, the SPSS 22.0 [SPSS, Chicago, IL], and GraphPad Prism 6 
[San Diego, CA] programs were used. A 2-sided probability value of <0.05 
was considered to be statistically significant. 
 
RESULTS 
Serum levels of lectin pathway molecules in cirrhosis 
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Serum levels of lectin pathway molecules in patients with cirrhosis and the 
control group are presented in Table 2. FCN-2, FCN-3 and MASP-2 levels 
were significantly lower in patients with cirrhosis compared to healthy subjects. 
Similarly, MASP-2 deficiency occurred more often in patients with cirrhosis.  
In cirrhosis, levels of all three lectin pathway molecules decreased 
gradually according to disease severity, as rated by the Child-Pugh stage. 
Furthermore, both types of the FCNs but not the MASP-2 levels were 
significantly lower in patients with ascites as compared to those without 
(Table 2).  
FCN levels were also associated with disease etiology to some degree. 
FCN-2 and 3 levels were significantly lower in alcoholic as compared to non-
alcoholic patients, but only in patients with Child A stage (FCN-2: 505 [440 – 
562] vs. 548 [489 – 679] ng/ml, p=0.001 and FCN-3: 7509 [5508 – 10897] vs. 
10596 [7065 – 15379] ng/ml, p<0.001, respectively), or in those without 
ascites (data not shown). No similar association was found in the case of 
MASP-2 (Table 2).  
Significant correlation was found between levels of lectin pathway 
molecules and laboratory markers of impaired renal and liver function and 
accordingly with liver-oriented scores (Child-Pugh and MELD). Non-
parametric correlations are summarized in Table 3.  
 
Significance of serum levels of lectin pathway molecules in the risk of 
clinically significant bacterial infections 
Ninety-five (35.7%) of involved patients encountered at least one episode of 
CSI during the follow-up period. The median time to the development of first 
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infectious episode was 626 [169-799] days. Urinary tract infection was the 
most commonly diagnosed CSI and accounted for 33.7% of events, followed 
by SBP (24.2%) and pneumonia (12.6%). 5.3% of the cases were multifocal. 
Other sites of bacterial infections were as follows: erysipelas (4.2%), 
cholangitis (2.1%), bacteremia (2.1%), acute bronchitis (3.2%) and 
unidentified in 12 (12.6%) cases. 
 Low FCN-2 and FCN-3 levels were associated with an increased 
cumulative probability of CSI compared to normal level of the molecules 
(62.6% vs. 46.7% for FCN-2 with HR: 1.55, 95%CI: 1.00-2.39, p=0.047 and 
59.3% vs. 48.2% for FCN-3 with HR: 1.61, 95%CI: 1.05-2.47, p=0.029) (Table 
4). FCN serum profile, considering both levels of FCN molecules, showed an 
ever-increasing cumulative risk for development of CSI with increasing 
number of low FCN levels. Patients with normal level of both FCNs had a 
cumulative probability of 45.7% to develop a CSI, while those with low level of 
one or two FCNs had 57.2% and 63.8%, respectively (HR [95%CI]: 1.39 
[0.87-2.22], p=0.164 and 2.00 [1.15-3.47], p=0.016, respectively) (Table 4 and 
Figure 1A). No similar association was found, however, in the case of MASP-
2 deficiency either individually (Table 4 and Figure 1B) or in combination with 
FCN levels (data not shown).  
 
Covariates 
Analysis of clinical factors associated with development of CSI, using 
univariate Cox regression analysis, is shown in Table 4. Alcoholic disease 
etiology (HR: 1.68, 95%CI: 1.07-2.66, p=0.024), advanced disease stage 
(Child-Pugh stage B/C [HR: 2.42, 95%CI: 1.61-3.64, p<0.001] or presence of 
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ascites [HR: 2.31, 95%CI: 1.54-3.46, p<0.001]) and prior CSI episode (HR: 
2.64, 95%CI: 1.76-3.96, p<0.001) were significantly associated with the 
increased risk for the development of CSI. 
 
Multivariate analysis 
Cox regression analysis and the backward elimination procedure, taking 
serum levels of the lectin pathway molecules and all clinical covariates into 
account, indicated that only clinical factor, such as advanced disease stage 
and prior CSI episode, but neither individual FCNs nor FCN serum profile 
were independently associated with the risk of CSI development (Table 4). 
 
Mortality 
Potential impact of FCN serum profile and MASP-2 deficiency on 
infection-related mortality was also evaluated (n=95). During the course of the 
first bacterial infection, 19 patients died (20%). Neither FCN serum profile nor 
MASP-2 deficiency at enrolment was associated with the risk of mortality 
during a subsequent bacterial infection in Kaplan-Meier survival analysis 
(Figure 1C and D). 
In the total cohort liver-related mortality occurred in 85 (32.0%) 
subjects. Kaplan-Meier survival analysis demonstrated a significantly worse 
survival in patients with advanced disease according to Child-Pugh stage 
(p<0.001) or ascites (p<0.001) or prior CSI episode (p=0.035). MASP-2 
deficiency (p=0.387) or FCN serum profile (p=0.093), however, were not 
associated with overall survival (Figure 1E and F). 
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DISCUSSION 
To our knowledge, this is, to date the largest study to investigate the complex 
association between serum levels of the lectin pathway molecules and the 
disease etiology along with severity in a large cohort of patients with cirrhosis.  
Of the lectin pathway molecules of the complement system, two sPRMs 
(FCN-2 and FCN-3) and one effector molecule were evaluated (MASP-2).  
Serum concentrations of the lectin pathway components were found to 
show large inter-individual variations in healthy adults [25]. In the present 
study MASP-2 levels [26] and occurrence of MASP-2 deficiency [24] 
corresponded to those reported previously, while FCN-2 and FCN-3 levels 
were lower. In the case of MASP-2, we applied a commercially available 
assay that is widely used in complement studies [24].The disparity for FCNs is 
supposedly attributable to the variations in the applied methology and 
research materials of different source. Since various methodologies are 
available, we adjusted an own in-house double-antibody sandwich ELISA 
system. Another complicating consideration for FCN could be the handling 
and source of protein standard. It is known, that values obtained from the 
calibration curve are different by virtue of whether recently isolated FCN 
preparation or stocked one was used [27]. 
In a large group of stable outpatients with cirrhosis (n=266), we found 
that serum levels of all three molecules were significantly lower compared to 
healthy controls. Two previous reports verify our findings. In a study of 
Laursen et al. [28], low levels of FCN-2 and FCN-3 were found in a small 
group of patients (n=20) with stable alcoholic cirrhosis compared with healthy 
controls. Likewise, significantly lower FCN-2 levels were reported in patients 
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(n=120) with chronic HBV infection related cirrhosis by Hoang et al. [29]. 
Contrary, in a single study of patients with chronic HCV infection [30], serum 
FCN-2 levels were significantly higher in patients with cirrhosis (n=21) than 
those in the control and other patient groups including chronic inactive or 
active HCV patients without cirrhosis. The reason, why serum levels of lectin 
pathway molecules are decreased in most of the patients with cirrhosis is yet 
to be elucidated. One reasonable explanation could be that in cirrhosis, 
synthetic capacity of hepatocytes is damaged, that results in a decreased 
production of these proteins. This assumption is supported by our findings 
that FCN-2, FCN-3 and MASP-2 levels showed gradual decrease according 
to disease severity. 
When the adaptive immune response is immature or compromised, the 
innate immune system constitutes the principle defense against infection. 
Clinical studies have shown that common functional gen polymorphisms in 
FNC2 [27], FCN3 [16] and MASP2 [15], which affect the composition, 
structure and function of respective proteins, confer an increased risk for 
various bacterial infections particularly in immunocompromised patients. 
Cirrhosis has been characterized as an acquired immunodeficiency syndrome 
[31]. Thus, it is reasonable to assume that serum levels of the lectin pathway 
molecules might be related to the bacterial infectious episodes among 
patients with cirrhosis; however, it has not been evaluated so far. Accordingly, 
we conducted a follow-up observational study to assess whether the low level 
of FCNs or MASP-2 deficiency constitutes a risk for the development of CSI in 
patients with cirrhosis. 
Several SNPs in the promoter and the encoding region of FCN2 and 
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MASP2 gene have been implicated in influencing protein concentrations but 
relatively few SNP has been identified in FCN3 gene [15,16]. Considerable 
linkage disequilibrium occurs between pairs of promoter and structural gene 
dimorphisms, confounding the investigation of the relationship between allele 
expression and protein concentration [27]. Thus it has been clearly proved, 
that genotypes have very modest influence on average protein concentrations, 
each being associated with large and overlapping ranges [32]. Besides gene 
polymorphisms of the lectin pathway of complement system, up- and 
downregulation of these genes and increase or decrease of serum proteins 
also appears to be associated with various infectious and inflammatory 
diseases [16]. Due to these limitations we evaluated serum level of the 
molecules instead of genotyping.  
Regarding serological markers, however one could take into 
consideration various factors, that might influence stability of the serum level 
of molecule. Acute phase reaction might be such a factor, thus to avoid 
interfering effect of acute complication of the disease on the synthesis of the 
molecules, only stable outpatients were involved in the present study. 
Moreover, in a subgroup of patients (n=32) we carefully evaluated whether 
the level of FCN-2, FCN-3 and MASP-2 are stable over time. They have a 
subsequent sample from a later outpatient visit with time-lag of 655 [IQR: 246-
1090] days. Median time between sample procurements was comparable with 
the time to first CSI episode. None of the serum level of these molecules 
showed significant changes (FCN-2: 504 [458-600] vs. 479 [423-543], 
p=0.092; FCN-3: 9449 [5934-13070] vs. 8814 [5999-11006], p=0.837; MASP-
2: 221 [129-369] vs. 208 [119-324], p=0.313). No significant change in 
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patients’ Child-Pugh category was observed during this time period (p=1.000 
with Wilcoxon signed ranks test).  
Low level of sPRMs can lead to insufficient recognition of microbes and 
decreased complement activation, opsonization and inflammatory cytokine 
secretion, which results in increased susceptibility to infections [33]. In 
Kaplan-Meier analysis, in patients with low level of either FCN-2 or FCN-3 the 
cumulative probability of CSI was significantly higher, compared to those with 
normal level. Moreover, considering both levels of FCN molecules a step-wise 
increase was observed in the risk of the CSI development with increasing 
number of low FCN levels. In the multivariate Cox-regression analysis, 
adjusting for Child-Pugh category, however, these associations were not 
found to be independent from diseases severity. This might support the notion, 
that decreased level of FCNs are related to deterioration of synthetic capacity 
of hepatocytes. And also suggests that low level of FCNs is an additional 
constituent of cirrhosis-associated immune deficiency and increased risk of 
CSI in this patient population.  
MASP-2 is the central but not a single activator of the lectin pathway. 
After lectin type sPRMs bind their targets, MASPs are cleaved and activated 
and set in motion a proteolytic cascade, which culminates in formation of the 
membrane attack complex and pathogen lysis [15]. In the present study, 
serum MASP-2 level was not associated with the risk of developing a CSI. 
However, we did not perform functional analysis that is an indisputable 
limitation of our study. MASP-2 antigen level not necessarily indicates the 
function of the molecule and scarcely assessed in previous studies. One 
cannot exclude that MASP-2 activity could have been associated with this 
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outcome. 
 Finally, serum level of lectin pathway components at enrolment was 
also not associated with the infection-related mortality. Since complement 
system has a dual role in disease susceptibility, one can expect that during an 
on-going inflammatory process rather its excessive activation with subsequent 
tissue damage than its lack of activity poses a risk of harm to the host. 
Another important consideration is that serum level of these molecules might 
change during acute phase reactions like bacterial infection. We did not re-
assess serum samples during the first CSI episodes, which is evidently 
another limitation of this analysis. These issues warrant further evaluation in 
future studies of the lectin pathway in cirrhosis.  
 In conclusion, findings of our large referral cohort study indicate that 
serum level of the lectin complement pathway molecules are decreased in 
cirrhosis and are related to the disease severity verifying importance of the 
liver in the production of FCNs and MASP-2. Moreover, low levels of soluble 
pattern recognition FCN molecules might be considered as an additional 
constituent of cirrhosis-associated immune dysfunction resulting in an 
increased risk of bacterial infections in this patient population.  
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Figure Legends 
Fig. 1. Development of bacterial infection (A,B) (n=266), infection-related 
mortality (C,D) (n=95) and liver-related mortality (E,F) (n=266) in 
cirrhosis according to serum level of ficolins (FCNs) or mannan-binding 
lectin serine protease-2 (MASP-2). 
 
Patients with low level of both FCNs have higher cumulative probability of CSI 
compared to those with normal or low level of one FCN. MASP-2 deficiency 
was not associated with the risk of CSI development. Neither FCN serum 
profile and nor MASP-2 deficiency were associated with the infection-related 
or liver-related mortality. 
 
MASP-2 deficiency:<100ng/ml, low level of FCN-2:<427ng/ml and FCN-
3:<4857ng/ml 
* Log-Rank test 
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Tables 
Table 1. Clinical characteristics of patients with cirrhosis. 
 TOTAL Patients with 
alcoholic 
cirrhosis 
Patients with non-
alcoholic 
cirrhosis 
Number 266 170 96 
Gender (male/ female) 133/133 91/79 42/54 
Age (years)a 56 (49-64) 53 (47-64) 57 (51-63) 
Child-Pugh stage, n(%) 
A 
B 
C 
 
148 (55.6) 
101 (38.0) 
17 (6.4) 
 
83 (48.8) 
75 (44.1) 
12 (7.1) 
 
65 (67.7) 
26 (27.1) 
5 (5.2)♯ 
MELD score a 11 (8-14) 12 (9-14) 10 (7-13)♯ 
Serum bilirubin (µmol/L) a 27 (16-42) 28 (18-44) 22 (13-37)♯ 
Serum albumin (g/L) a 38 (33-42) 37 (32-42) 39 (34-44)♯ 
INR a 1.2 (1.1-1.3) 1.2 (1.1-1.3) 1.1 (1.1-1.3)♯ 
Ascites, n(%) 96 (38.1) 74 (43.5) 22 (22.9)♯ 
Co-morbidity, n(%) 136 (51.1) 91 (53.5) 45 (46.9) 
HCC, n(%) 26 (9.8) 16 (9.4) 10 (10.4) 
Prior CSI, n(%) 97 (36.5) 71 (41.8) 26 (27.1)♯ 
CSI: clinically significant bacterial infection; HCC: hepatocellular carcinoma; INR: 
international normalized ratio; amedian, IQR (lowest 25% - highest 25%)  
♯p<0.01 between patients with alcoholic vs. non-alcoholic cirrhosis 
p values were calculated by Mann-Whitney U-test, Fisher’s exact test or χ
2
-test with 
Yates correction as appropriate 
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Table 2. Levels of lectin pathway molecules in patients with cirrhosis and healthy controls. 
 Number FCN-2 level  
(ng/ml) a 
FCN-3 level  
(ng/ml) a 
MASP-2 level  
(ng/ml)a 
MASP-2 deficiency  
(< 100 ng/ml), n(%) 
Healthy controls 160 769  
(629 – 1145) 
10797 
(9017 – 13867) 
412 
(285 – 586) 
3 
(2.0) 
Cirrhosis with  
various etiology 
266 505  
(426 – 596) ♯ 
7301 
(4857 – 10601) ♯ 
212 
(126 – 359) ♯ 
52  
(19.5) ♯ 
Alcoholic 170 492 
(398 – 564) 
6593 
(4532 – 9569) 
206 
(127 – 357) 
35 
(20.6) 
Non-alcoholic 96 536  
(470 – 652) ✕ 
9498 
(6318 – 13614) + 
234 
(123 – 363) 
17 
(17.7) 
Child-Pugh stage      
A 148 527 
(455 – 618) 
8962 
(6064 – 12872) 
250 
(159 – 372) 
22 
(14.9) 
B 101 486  
(391 – 583) 
6032 
(4416 – 8714) 
194  
(106 – 320) 
23 
(22.8) 
C 17 427 
(314 – 499)  
5487 
(3986 – 8139) ☐ 
134  
(56 – 295) § 
7 
(41.2) § 
Ascites      
No 170 528 
(453 – 625) 
8110 
(5764 – 12006) 
239 
(133 – 370) 
29  
(17.1) 
Yes 96 472 
(392 – 550) ± 
6314 
(4094 – 8917) ± 
195 
(103 – 335)  
23 
(24.0) 
FCN: ficolin; MASP: mannan-binding lectin serine protease; amedian, IQR (lowest 25% - highest 25%) 
♯p< 0.001 between cirrhosis and healthy controls;  
+p< 0.001 and ✕p< 0.01 between non-alcoholics and alcoholics  
☐p< 0.001, p< 0.01 and §p< 0.05 between three different Child groups 
Page 26 of 31Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
±p< 0.01 between no-ascites and ascites 
p values were calculated by Mann-Whitney U-test, Fisher’s exact test or χ
2
-test with Yates correction as appropriate 
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Table 3. Nonparametric correlation between serum levels of lectin 
pathway molecules and laboratory characteristic of patients with 
cirrhosis 
 
 FCN-2 level FCN-3 level MASP-2 level 
 Spearman’s 
rho 
p-value Spearman’s 
rho 
p-value Spearman’s 
rho 
p-value 
Age -0.014 0.815 0.007 0.915 0.05 0.415 
Creatinine 0.087 0.168 0.066 0.293 0.094 0.137 
Bilirubin -0.292 <0.001 -0.441 <0.001 -0.249 <0.001 
Albumin 0.184 0.003 0.317 <0.001 -0.300 <0.001 
INR -0.300 <0.001 -0.442 <0.001 -0.240 <0.001 
CPS -0.263 <0.001 -0.390 <0.001 -0.205 0.001 
MELD -0.193 0.002 -0.404 <0.001 -0.256 <0.001 
AST 0.143 0.020 0.177 0.004 0.031 0.620 
ALT 0.200 0.001 0.299 <0.001 0.104 0.089 
Platelet 0.086 0.168 0.127 0.038 0.090 0.143 
FCN: ficolin; MASP: mannan-binding lectin serine protease; CPS: Child-Pugh score; 
INR: international normalized ratio, AST: aspartate aminotransferase; ALT: alanine 
aminotransferase 
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Table 4. Univariate and multivariate Cox-regression analysis for the 
association of serum levels of lectin pathway molecules and clinical 
factors with the cumulative incidence of clinically significant bacterial 
infection in patients with cirrhosis. 
. . 
CSI 
development . . 
Univariate 
analysis . 
Mulivariate 
analysis . 
. . 
n of 
subject 
n of 
event 
CP of 
CSI % 
p- 
value* HR (95% CI) 
p- 
value HR (95% CI) 
p- 
value 
Total 
cohort 266 95 50.6% - 
Age 
<65 216 74 47.9% 
>65 50 21 64.2% 0.173 1.40 (0.86-2.28) 0.175 
Gender 
male 133 48 48.7% 
female 133 47 53.0% 0.676 1.09 (0.73-1.63) 0.676 
Co- 
morbidity 
absent 130 42 44.5% 
present 136 53 57.4% 0.132 1.37 (0.91-2.05) 0.136 
Etiology 
other 96 25 41.6% 
alcoholic 170 70 55.5% 0.024 1.68 (1.07-2.66) 0.025 1.36 (0.85-2.15) 0.196 
Prior CSI 
absent 169 42 38.8% 
present 97 53 68.7% <0.001 2.64 (1.76-3.96) <0.001 2.48 (1.65-3.73) <0.001 
Child-Pugh 
stage 
Child A 148 43 40.1% 
Child B/C 118 52 66.8% <0.001 2.42 (1.61-3.64) <0.001 2.27 (1.51-3.41) <0.001 
PPI use 
no 148 43 41.8% 
yes 118 52 61.3% 0.005 1.76 (1.18-2.64) 0.006 1.25 (0.81-1.91) 0.317 
NSBB use 
no 139 42 43.1% 
yes 127 53 58.7% 0.033 1.55 (1.03-2.32) 0.034 1.08 (0.67-1.74) 0.753 
Ascites 
absent 170 52 42.3% 
present 96 43 67.9% <0.001 2.31 (1.54-3.46) <0.001 
MASP-2 
normal 214 74 48.6% 
deficient 52 21 59.6% 0.306 1.29 (0.79-2.09) 0.307 
FCN-2  
normal  200 65 46.7% 
low level 66 30 62.6% 0.047 1.55 (1.00-2.39) 0.049 1.09 (0.69-1.72) 0.715 
FCN-3 
normal  200 64 48.2% 
low level 66 31 59.3% 0.029 1.61 (1.05-2.47) 0.030 1.00 (0.63-1.58) 0.985 
Combined  
FCNs 
normal  167 51 45.7% ref. 
low level  
of one 
FCN 66 27 57.2% 0.160 1.39 (0.87-2.22) 0.164 0.97 (0.59-1.59) 0.908 
low level 
of both 
FCNs 33 17 63.8% 0.016 2.00 (1.15-3.47) 0.014 1.09 (0.60-1.99) 0.770 
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* p-values of the log-rank tests;  
CP: cumulative probability; CI: confidence interval; CSI: clinically significant bacterial 
infections; FCN: ficolin; HR: hazard ratio; MASP: mannan-binding lectin serine 
protease; NSBB: non-selective beta blocker; PPI: proton-pump inhibitor; ref.: 
reference 
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